{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T03:34:04Z","timestamp":1774150444718,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"41","license":[{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2011,10,13]]},"DOI":"10.1038\/onc.2011.133","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T10:15:14Z","timestamp":1304936114000},"page":"4243-4260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours"],"prefix":"10.1038","volume":"30","author":[{"given":"N","family":"Rajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Clewes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Burn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Langtry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sieber-Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J","family":"Lord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,9]]},"reference":[{"key":"BFonc2011133_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1365-2133.2005.06763.x","volume":"153","author":"MA Adly","year":"2005","unstructured":"Adly MA, Assaf HA, Nada EA, Soliman M, Hussein M . (2005). Human scalp skin and hair follicles express neurotrophin-3 and its high-affinity receptor tyrosine kinase C, and show hair cycle-dependent alterations in expression. Br J Dermatol 153: 514\u2013520.","journal-title":"Br J Dermatol"},{"key":"BFonc2011133_CR2","doi-asserted-by":"publisher","first-page":"37170","DOI":"10.1074\/jbc.M705414200","volume":"282","author":"R Alvarez-Rodr\u00edguez","year":"2007","unstructured":"Alvarez-Rodr\u00edguez R, Barzi M, Berenguer J, Pons S . (2007). Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. J Biol Chem 282: 37170\u201337180.","journal-title":"J Biol Chem"},{"key":"BFonc2011133_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","volume":"12","author":"CM Annunziata","year":"2007","unstructured":"Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. (2007). Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115\u2013130.","journal-title":"Cancer Cell"},{"key":"BFonc2011133_CR4","doi-asserted-by":"publisher","first-page":"e8162","DOI":"10.1371\/journal.pone.0008162","volume":"4","author":"C April","year":"2009","unstructured":"April C, Klotzle B, Royce T, Wickham-Garcia E, Boyaniwsky T, Izzo J et al. (2009). Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One 4: e8162.","journal-title":"PLoS One"},{"key":"BFonc2011133_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.neuron.2006.03.044","volume":"50","author":"JC Ar\u00e9valo","year":"2006","unstructured":"Ar\u00e9valo JC, Waite J, Rajagopal R, Beyna M, Chen Z-Y, Lee FS et al. (2006). Cell survival through Trk neurotrophin receptors is differentially regulated by ubiquitination. Neuron 50: 549\u2013559.","journal-title":"Neuron"},{"key":"BFonc2011133_CR6","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00403-005-0563-y","volume":"296","author":"H Blasing","year":"2005","unstructured":"Blasing H, Hendrix S, Paus R . (2005). Pro-inflammatory cytokines upregulate the skin immunoreactivity for NGF, NT-3, NT-4 and their receptor, p75NTR in vivo: a preliminary report. Arch Dermatol Res 296: 580\u2013584.","journal-title":"Arch Dermatol Res"},{"key":"BFonc2011133_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.0022-202X.2005.23688.x","volume":"124","author":"S Bowen","year":"2005","unstructured":"Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, Vazquez ME et al. (2005). Mutations in the CYLD gene in Brooke\u2013Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype\u2013phenotype correlation. J Invest Dermatol 124: 919\u2013920.","journal-title":"J Invest Dermatol"},{"key":"BFonc2011133_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/1523-1747.ep12470965","volume":"96","author":"L Bruckner-Tuderman","year":"1991","unstructured":"Bruckner-Tuderman L, Pfaltz M, Schnyder UW . (1991). Cylindroma overexpresses collagen VII, the major anchoring fibril protein. J Invest Dermatol 96: 729\u2013734.","journal-title":"J Invest Dermatol"},{"key":"BFonc2011133_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nature01811","volume":"424","author":"TR Brummelkamp","year":"2003","unstructured":"Brummelkamp TR, Nijman SM, Dirac AM, Bernards R . (2003). Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424: 797\u2013801.","journal-title":"Nature"},{"key":"BFonc2011133_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/geno.1995.1100","volume":"28","author":"MG Butti","year":"1995","unstructured":"Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA . (1995). A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics 28: 15\u201324.","journal-title":"Genomics"},{"key":"BFonc2011133_CR11","first-page":"1009","volume":"30","author":"CP Chen-Tsai","year":"2004","unstructured":"Chen-Tsai CP, Colome-Grimmer M, Wagner RF . (2004). Correlations among neural cell adhesion molecule, nerve growth factor, and its receptors, TrkA, TrkB, TrkC, and p75, in perineural invasion by basal cell and cutaneous squamous cell carcinomas. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery (et al) 30: 1009\u20131016.","journal-title":"Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery (et al)"},{"key":"BFonc2011133_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ygeno.2006.12.012","volume":"89","author":"BP Coe","year":"2007","unstructured":"Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL . (2007). Resolving the resolution of array CGH. Genomics 89: 647\u2013653.","journal-title":"Genomics"},{"key":"BFonc2011133_CR13","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","volume":"115","author":"YN Demchenko","year":"2010","unstructured":"Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM . (2010). Classical and\/or alternative NF B pathway activation in multiple myeloma. Blood 115: 3541\u20133552.","journal-title":"Blood"},{"key":"BFonc2011133_CR14","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/j.1524-4725.2009.01236.x","volume":"35","author":"J Donovan","year":"2009","unstructured":"Donovan J . (2009). Review of the hair follicle origin hypothesis for basal cell carcinoma. Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery (et al) 35: 1311\u20131323.","journal-title":"Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery (et al)"},{"key":"BFonc2011133_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2105-9-85","volume":"9","author":"MJ Dunning","year":"2008","unstructured":"Dunning MJ, Barbosa-Morais NL, Lynch AG, Tavar\u00e9 S, Ritchie ME . (2008). Statistical issues in the analysis of Illumina data. BMC Bioinformatics 9: 85.","journal-title":"BMC Bioinformatics"},{"key":"BFonc2011133_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1046\/j.1440-1681.1999.03108.x","volume":"26","author":"R Dutton","year":"1999","unstructured":"Dutton R, Yamada T, Turnley A, Bartlett PF, Murphy M . (1999). Regulation of spinal motoneuron differentiation by the combined action of Sonic hedgehog and neurotrophin 3. Clin Exp Pharmacol Physiol 26: 746\u2013748.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFonc2011133_CR17","doi-asserted-by":"publisher","first-page":"8802","DOI":"10.1074\/jbc.M708470200","volume":"283","author":"J Gao","year":"2008","unstructured":"Gao J, Huo L, Sun X, Liu M, Li D, Dong JT et al. (2008). The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 283: 8802\u20138809.","journal-title":"J Biol Chem"},{"key":"BFonc2011133_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.molcel.2005.09.014","volume":"20","author":"T Geetha","year":"2005","unstructured":"Geetha T, Jiang J, Wooten MW . (2005). Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Mol Cell 20: 301\u2013312.","journal-title":"Mol Cell"},{"key":"BFonc2011133_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bbrc.2008.06.082","volume":"374","author":"T Geetha","year":"2008","unstructured":"Geetha T, Seibenhener ML, Chen L, Madura K, Wooten MW . (2008). p62 serves as a shuttling factor for TrkA interaction with the proteasome. Biochem Biophys Res Commun 374: 33\u201337.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2011133_CR20","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/1097-0142(19930901)72:5<1618::AID-CNCR2820720521>3.0.CO;2-5","volume":"72","author":"AL Gerretsen","year":"1993","unstructured":"Gerretsen AL, van der Putte SC, Deenstra W, van Vloten WA . (1993). Cutaneous cylindroma with malignant transformation. Cancer 72: 1618\u20131623.","journal-title":"Cancer"},{"key":"BFonc2011133_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/gcc.20575","volume":"47","author":"R Gunnarsson","year":"2008","unstructured":"Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U et al. (2008). Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia\u2014a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 47: 697\u2013711.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2011133_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/carcin\/bgl081","volume":"28","author":"C Hellerbrand","year":"2007","unstructured":"Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK . (2007). Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28: 21\u201327.","journal-title":"Carcinogenesis"},{"key":"BFonc2011133_CR23","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ng.192","volume":"40","author":"S Hoseong Yang","year":"2008","unstructured":"Hoseong Yang S, Andl T, Grachtchouk V, Wang A, Liu J, Syu L et al. (2008). Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt\/\u03b2-catenin signaling. Nat Genet 40: 1130\u20131135.","journal-title":"Nat Genet"},{"key":"BFonc2011133_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","volume":"24","author":"EJ Huang","year":"2001","unstructured":"Huang EJ, Reichardt LF . (2001). Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677\u2013736.","journal-title":"Annu Rev Neurosci"},{"key":"BFonc2011133_CR25","unstructured":"Illumina Inc. (2009). Beadstudio Gene Expression Module v3.4 User Guide (113172615 Rev A) Illumina Inc.: San Diego, CA."},{"key":"BFonc2011133_CR26","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood-2007-02-075069","volume":"110","author":"MW Jenner","year":"2007","unstructured":"Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D et al. (2007). Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110: 3291\u20133300.","journal-title":"Blood"},{"key":"BFonc2011133_CR27","doi-asserted-by":"publisher","first-page":"9869","DOI":"10.1158\/0008-5472.CAN-07-0436","volume":"67","author":"W Jin","year":"2007","unstructured":"Jin W, Yun C, Kim H-S, Kim S-J . (2007). TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res 67: 9869\u20139877.","journal-title":"Cancer Res"},{"key":"BFonc2011133_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-1","volume":"9","author":"DO Kavanagh","year":"2009","unstructured":"Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F et al. (2009). Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9: 1.","journal-title":"BMC Cancer"},{"key":"BFonc2011133_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"J Keats","year":"2007","unstructured":"Keats J, Fonseca R, Chesi M, Schop R, Baker A, Chng W et al. (2007). Promiscuous mutations activate the noncanonical NF-\u03baB Pathway in multiple myeloma. Cancer Cell 12: 131\u2013144.","journal-title":"Cancer Cell"},{"key":"BFonc2011133_CR30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ijc.23590","volume":"123","author":"N Kikuno","year":"2008","unstructured":"Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y et al. (2008). Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 123: 552\u2013560.","journal-title":"Int J Cancer"},{"key":"BFonc2011133_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.molcel.2007.12.018","volume":"29","author":"D Komander","year":"2008","unstructured":"Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A et al. (2008). The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 29: 451\u2013464.","journal-title":"Mol Cell"},{"key":"BFonc2011133_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nature01802","volume":"424","author":"A Kovalenko","year":"2003","unstructured":"Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G . (2003). The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801\u2013805.","journal-title":"Nature"},{"key":"BFonc2011133_CR33","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1365-2133.2009.09144.x","volume":"160","author":"L Kriegl","year":"2009","unstructured":"Kriegl L, Horst D, Kirchner T, Jung A . (2009). LEF-1 expression in basal cell carcinomas. Br J Dermatol 160: 1353\u20131356.","journal-title":"Br J Dermatol"},{"key":"BFonc2011133_CR34","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/onc.2009.61","volume":"28","author":"C Lagadec","year":"2009","unstructured":"Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R et al. (2009). TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28: 1960\u20131970.","journal-title":"Oncogene"},{"key":"BFonc2011133_CR35","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J . (2006). The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929\u20131935.","journal-title":"Science"},{"key":"BFonc2011133_CR36","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.1073\/pnas.0603089103","volume":"103","author":"H-H Liu","year":"2006","unstructured":"Liu H-H, Xie M, Schneider MD, Chen ZJ . (2006). Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci USA 103: 11677\u201311682.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011133_CR37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo J, Solimini NL, Elledge SJ . (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823\u2013837.","journal-title":"Cell"},{"key":"BFonc2011133_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/path.2423","volume":"216","author":"C Marchio","year":"2008","unstructured":"Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS et al. (2008). The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216: 399\u2013407.","journal-title":"J Pathol"},{"key":"BFonc2011133_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/B:DRUG.0000047103.64335.b0","volume":"23","author":"JL Marshall","year":"2005","unstructured":"Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N et al. (2005). Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23: 31\u201337.","journal-title":"Invest New Drugs"},{"key":"BFonc2011133_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/319743a0","volume":"319","author":"D Martin-Zanca","year":"1986","unstructured":"Martin-Zanca D, Hughes SH, Barbacid M . (1986). A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319: 743\u2013748.","journal-title":"Nature"},{"key":"BFonc2011133_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2006.03.041","volume":"125","author":"R Massoumi","year":"2006","unstructured":"Massoumi R . (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-\u03baB signaling. Cell 125: 665\u2013677.","journal-title":"Cell"},{"key":"BFonc2011133_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2006.03.041","volume":"125","author":"R Massoumi","year":"2006","unstructured":"Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R . (2006). Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125: 665\u2013677.","journal-title":"Cell"},{"key":"BFonc2011133_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1084\/jem.20082044","volume":"206","author":"R Massoumi","year":"2009","unstructured":"Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T et al. (2009). Downregulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206: 221\u2013232.","journal-title":"J Exp Med"},{"key":"BFonc2011133_CR44","first-page":"1798","volume":"55","author":"K Matsumoto","year":"1995","unstructured":"Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ . (1995). Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 55: 1798\u20131806.","journal-title":"Cancer Res"},{"key":"BFonc2011133_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/00000372-199704000-00009","volume":"19","author":"M Meybehm","year":"1997","unstructured":"Meybehm M, Fischer HP . (1997). Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol 19: 154\u2013161.","journal-title":"Am J Dermatopathol"},{"key":"BFonc2011133_CR46","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bcp.2009.12.021","volume":"79","author":"SC Miller","year":"2010","unstructured":"Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P et al. (2010). Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 79: 1272\u20131280.","journal-title":"Biochem Pharmacol"},{"key":"BFonc2011133_CR47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-009-0501-3","volume":"121","author":"R Natrajan","year":"2009","unstructured":"Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DSP et al. (2009). An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 121: 575\u2013589.","journal-title":"Breast Cancer Res Treat"},{"key":"BFonc2011133_CR48","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1073\/pnas.97.7.3438","volume":"97","author":"M Nilsson","year":"2000","unstructured":"Nilsson M, Und\u00e8n AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG et al. (2000). Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci USA 97: 3438\u20133443.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011133_CR49","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1365-2133.2006.07224.x","volume":"155","author":"HM Oosterkamp","year":"2006","unstructured":"Oosterkamp HM, Neering H, Nijman SM, Dirac AM, Mooi WJ, Bernards R et al. (2006). An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. Br J Dermatol 155: 182\u2013185.","journal-title":"Br J Dermatol"},{"key":"BFonc2011133_CR50","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj.onc.1209029","volume":"25","author":"W Qiao","year":"2006","unstructured":"Qiao W, Li AG, Owens P, Xu X, Wang X-J, Deng C-X . (2006). Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. Oncogene 25: 207\u2013217.","journal-title":"Oncogene"},{"key":"BFonc2011133_CR51","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/archdermatol.2009.262","volume":"145","author":"N Rajan","year":"2009","unstructured":"Rajan N, Langtry JAA, Ashworth A, Roberts C, Chapman P, Burn J et al. (2009). Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol 145: 1277\u20131284.","journal-title":"Arch Dermatol"},{"key":"BFonc2011133_CR52","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1084\/jem.20062694","volume":"204","author":"WW Reiley","year":"2007","unstructured":"Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF et al. (2007). Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 204: 1475\u20131485.","journal-title":"J Exp Med"},{"key":"BFonc2011133_CR53","doi-asserted-by":"publisher","first-page":"55161","DOI":"10.1074\/jbc.M411049200","volume":"279","author":"W Reiley","year":"2004","unstructured":"Reiley W, Zhang M, Sun S-C . (2004). Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 279: 55161\u201355167.","journal-title":"J Biol Chem"},{"key":"BFonc2011133_CR54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/ni1315","volume":"7","author":"WW Reiley","year":"2006","unstructured":"Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC et al. (2006). Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 7: 411\u2013417.","journal-title":"Nat Immunol"},{"key":"BFonc2011133_CR55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1165\/ajrcmb.25.4.4470","volume":"25","author":"A Ricci","year":"2001","unstructured":"Ricci A, Greco S, Mariotta S, Felici L, Bronzetti E, Cavazzana A et al. (2001). Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 25: 439\u2013446.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"BFonc2011133_CR56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/jmg.2007.056127","volume":"45","author":"S Saggar","year":"2008","unstructured":"Saggar S, Chernoff KA, Lodha S, Horev L, Kohl S, Honjo RS et al. (2008). CYLD mutations in familial skin appendage tumours. J Med Genet 45: 298\u2013302.","journal-title":"J Med Genet"},{"key":"BFonc2011133_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11481-006-9020-8","volume":"1","author":"RN Saha","year":"2006","unstructured":"Saha RN, Liu X, Pahan K . (2006). Upregulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 1: 212\u2013222.","journal-title":"J Neuroimmune Pharmacol"},{"key":"BFonc2011133_CR58","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1471-4159.2004.02365.x","volume":"89","author":"HS Saini","year":"2004","unstructured":"Saini HS, Gorse KM, Boxer LM, Sato-Bigbee C . (2004). Neurotrophin-3 and a CREB-mediated signaling pathway regulate Bcl-2 expression in oligodendrocyte progenitor cells. J Neurochem 89: 951\u2013961.","journal-title":"J Neurochem"},{"key":"BFonc2011133_CR59","first-page":"3737","volume":"56","author":"S Scala","year":"1996","unstructured":"Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler JL, Spengler BA et al. (1996). Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 56: 3737\u20133742.","journal-title":"Cancer Res"},{"key":"BFonc2011133_CR60","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/13543781003598862","volume":"19","author":"M Shabbir","year":"2010","unstructured":"Shabbir M, Stuart R . (2010). Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Invest Drugs 19: 427\u2013436.","journal-title":"Expert Opin Invest Drugs"},{"key":"BFonc2011133_CR61","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1073\/pnas.0703268104","volume":"104","author":"F Stegmeier","year":"2007","unstructured":"Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ . (2007). The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 104: 8869\u20138874.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011133_CR62","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.cellsig.2005.12.009","volume":"18","author":"A Stokes","year":"2006","unstructured":"Stokes A, Wakano C, Koblan-Huberson M, Adra CN, Fleig A, Turner H . (2006). TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18: 1584\u20131594.","journal-title":"Cell Signal"},{"key":"BFonc2011133_CR63","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545\u201315550.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011133_CR64","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/bioinformatics\/btl117","volume":"22","author":"R Suzuki","year":"2006","unstructured":"Suzuki R, Shimodaira H . (2006). Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22: 1540\u20131542.","journal-title":"Bioinformatics"},{"key":"BFonc2011133_CR65","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/labinvest.3700593","volume":"87","author":"DS Tan","year":"2007","unstructured":"Tan DS, Lambros MB, Natrajan R, Reis-Filho JS . (2007). Getting it right: designing microarray (and not \u2018microawry\u2019) comparative genomic hybridization studies for cancer research. Lab Invest 87: 737\u2013754.","journal-title":"Lab Invest"},{"key":"BFonc2011133_CR66","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.molcel.2010.01.035","volume":"37","author":"DVF Tauriello","year":"2010","unstructured":"Tauriello DVF, Haegebarth A, Kuper I, Edelmann MJ, Henraat M, Canninga-van Dijk MR et al. (2010). Loss of the tumor suppressor CYLD enhances Wnt\/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 37: 607\u2013619.","journal-title":"Mol Cell"},{"key":"BFonc2011133_CR67","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1158\/0008-5472.CAN-05-0842","volume":"65","author":"M-T Teh","year":"2005","unstructured":"Teh M-T, Blaydon D, Chaplin T, Foot NJ, Skoulakis S, Raghavan M et al. (2005). Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 65: 8597\u20138603.","journal-title":"Cancer Res"},{"key":"BFonc2011133_CR68","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00000372-199506000-00008","volume":"17","author":"O Tellechea","year":"1995","unstructured":"Tellechea O, Reis JP, Ilheu O, Baptista AP . (1995). Dermal cylindroma. An immunohistochemical study of thirteen cases. Am J Dermatopathol 17: 260\u2013265.","journal-title":"Am J Dermatopathol"},{"key":"BFonc2011133_CR69","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1158\/1535-7163.MCT-09-0036","volume":"8","author":"K Thress","year":"2009","unstructured":"Thress K, Macintyre T, Wang H, Whitston D, Liu ZY, Hoffmann E et al. (2009). Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 8: 1818\u20131827.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2011133_CR70","first-page":"25","volume":"108","author":"R Timpl","year":"1984","unstructured":"Timpl R, Fujiwara S, Dziadek M, Aumailley M, Weber S, Engel J . (1984). Laminin, proteoglycan, nidogen and collagen IV: structural models and molecular interactions. Ciba Found Symp 108: 25\u201343.","journal-title":"Ciba Found Symp"},{"key":"BFonc2011133_CR71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nature01803","volume":"424","author":"E Trompouki","year":"2003","unstructured":"Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G . (2003). CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793\u2013796.","journal-title":"Nature"},{"key":"BFonc2011133_CR72","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1593\/neo.81424","volume":"11","author":"E Trompouki","year":"2009","unstructured":"Trompouki E, Tsagaratou A, Kosmidis SK, Doll\u00e9 P, Qian J, Kontoyiannis DL et al. (2009). Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 11: 469\u2013476.","journal-title":"Neoplasia"},{"key":"BFonc2011133_CR73","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0002-9440(10)64865-1","volume":"160","author":"L Tunggal","year":"2002","unstructured":"Tunggal L, Ravaux J, Pesch M, Smola H, Krieg T, Gaill F et al. (2002). Defective laminin 5 processing in cylindroma cells. Am J Pathol 160: 459\u2013468.","journal-title":"Am J Pathol"},{"key":"BFonc2011133_CR74","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/onc.2009.489","volume":"29","author":"N Turner","year":"2010","unstructured":"Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R et al. (2010). Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013\u20132023.","journal-title":"Oncogene"},{"key":"BFonc2011133_CR75","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#","volume":"45","author":"AT Weeraratna","year":"2000","unstructured":"Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT . (2000). Rational basis for Trk inhibition therapy for prostate cancer. Prostate 45: 140\u2013148.","journal-title":"Prostate"},{"key":"BFonc2011133_CR76","doi-asserted-by":"publisher","first-page":"research0048","DOI":"10.1186\/gb-2002-3-9-research0048","volume":"3","author":"C Workman","year":"2002","unstructured":"Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, Nielser HB et al. (2002). A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 3: research0048.","journal-title":"Genome Biol"},{"key":"BFonc2011133_CR77","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/j.1600-0854.2007.00636.x","volume":"8","author":"C Wu","year":"2007","unstructured":"Wu C, Ramirez A, Cui B, Ding J, Delcroix J-DM, Valletta JS et al. (2007). A functional dynein-microtubule network is required for NGF signaling through the Rap1\/MAPK pathway. Traffic 8: 1503\u20131520.","journal-title":"Traffic"},{"key":"BFonc2011133_CR78","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1172\/JCI28746","volume":"116","author":"J Zhang","year":"2006","unstructured":"Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JMJ et al. (2006). Impaired regulation of NF-\u03baB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 116: 3042\u20133049.","journal-title":"J Clin Invest"},{"key":"BFonc2011133_CR79","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/sj.onc.1210041","volume":"26","author":"S Zhong","year":"2007","unstructured":"Zhong S, Fields CR, Su N, Pan Y-X, Robertson KD . (2007). Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26: 2621\u20132634.","journal-title":"Oncogene"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2011133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011133","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:27:15Z","timestamp":1647883635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2011133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,9]]},"references-count":79,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2011,10,13]]}},"alternative-id":["BFonc2011133"],"URL":"https:\/\/doi.org\/10.1038\/onc.2011.133","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,9]]},"assertion":[{"value":"3 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}